Abstract
Lymphoblastic lymphoma (LBL) accounts for approximately 4% of all adult patients with non-Hodgkin’s lymphoma (NHL). It is recognised as a distinct clinopathological entity in all of the recently described classifications for NHL, including the Revised European-AmeriPcan Lymphoma (REAL) classification. It is a neoplasm of precursor T or B lymphocytes, which is very similar to acute lymphoblastic leukaemia on the basis of morphology and phenotype. The distinction between ALL and LBL is variable between different treatment centres, and usually based on arbitrary clinical grounds, particularly the degree of bone marrow infiltration or leukaemic overspill. Because of its rarity, it has been the subject of relatively few series in the published literature, and several aspects of its management remain unclear. The results of treatment have improved in recent years, particularly with the use of intensive remission induction therapy similar to that used in acute lymphoblastic leukaemia (ALL). With intensive chemoradiotherapy, most recent series have reported remission rates of 60% to 80%, with long term disease free survival reported in 40% to 60% of patients. Therefore, although high remission rates can be achieved with conventional dose combination chemotherapy, the relapse and progression rate is high. The use of dose intensive therapy in first remission, particularly high dose therapy with stem cell transplantation, has been reported in several series, although its role remains unclear. Similarly, the selection of patients who are at high risk of relapse or progression with conventional therapy has not been reported consistently. The optimal management of patients who fail first line therapy also remains a difficult clinical problem.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
. Drexler H, Thiel E, Ludwig WD. Review of the incidence and clinical relevence of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia 1991; 5: 637
. Sixth international workshop on chromosomes in leukemia: London, England, May 11– 18,1987: Selected papers. Cancer Genet Cytogenet 1989; 40: 171
. Weiss L, Bindl J, Picozzi V, et al. Lymphoblastic lymphoma: An immunophenotypic study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood 1986; 67: 474
Swerdlow S, Habeshaw J, Richards M, et al. T lymphoblastic lymphoma with Leu-7 positive phenotype and unusual clinical course: A multiparameter study. Leuk Res 1985; 9: 167
. Sheibani K, Winberg C, Burke J. Lymphoblastic lymphoma expressing natural killer cell-associated antigens. A clinicopathologic study of six cases. Cancer 1987; 60: 183
. Sheibani K, Nathwani B, Winberg C. Antigenically defined subgroups of lymphoblastic lymphoma: Relationship to clinical presentation and biologic behavior. Cancer 1987; 60: 183
. Coleman CN, Picozzi VJ, Cox RS, et al. Treatment of lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 1626– 1637
. Morel P, Lepage E, Brice P, et al. Prognosis and treatment of lymphoblastic lymphoma in adults: A report on 80 patients. J Clin Oncol 1992; 10: 1078 – 1085
Bernasconi C, Brusamolino E, Lazzarino M, et al. Lymphoblastic lymphoma in adult patients; Clinico-pathological features and response to intensive multi agent chemotherapy analogous to that used in acute lymphoblastic leukemia. Ann Oncol 1990; 1: 141 – 146
. Slater DE, Mertelsmann R, Koriner B, et al. Lymphoblastic lymphoma in adults. J Clin Oncol 1986; 4: 57 – 67
Sweetenham JW, Mead GM, Whitehouse JMA. Adult lymphoblastic lymphoma: High incidence of central nervous system relapse in patients treated with the Stanford University protocol. Ann Oncol 1992; 3: 839 –841
. Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin’s lymphoma in children. A progress report on the original patients treated with the LSA2L2 protocol. Cancer 1979; 44: 1990 – 1999
The International Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987 – 994
Santini G, Coser P, Chisesi T, et al. Autologous bone marrow transplantation for advanced stage adult lymphoblastic lymphoma in first complete remission. Ann Oncol 1991; 2 (suppl 2): 181 – 185
Milpied N, Ifrah N, Kuentz M, et al. Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989; 73: 82 – 87
Verdonck LF, Dekker AW, de Gast GC, et al. Autologous bone marrow transplantation for adult poor risk lymphoblastic lymphoma in first remission. J Clin Oncol 1992; 10: 644 – 646
Jackson GH, Lennard AL, Taylor PRA, et al. Autologous bone marrow transplantation in poor risk high grade non-Hodgkin’s lymphoma in first complete remission. Br J Cancer 1994; 70: 501 – 505
. Sweetenham JW, Liberti G, Pearce R, et al. High dose therapy and autologous bone marrow transplanta¬tion for adult patients with lymphoblastic lymphoma: Results of the European Group for Bone Marrow Transplantation. J Clin Oncol 1994; 12: 1358 – 1365
Jost LM, Jacky E, Dommann-Scherrer C, et al. Short-term weekly chemotherapy followed by high-dose therapy with autologous bone marrow transplantation for lymphoblastic and Burkitt’s lymphomas in adult patients. Ann Oncol 1995; 6: 445 – 451
. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 1992; 11: 1690 – 1695
Shpall EJ, Jones RB, Bearman SI, et al. Transplantation of enriched CD34-positive autologous bone marrow into breast cancer patients following high dose chemotherapy: influence of CD34-positive pripheral blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28 – 31
Haas R, Witt B, Goldschmidt H, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754 – 3761
Sharp JC, Kessinger A, Mann S, et al. Detection and clinical significance of minimal tumor cell contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10 (suppl 2): 92 – 96
Gribben JG, Neuberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994; 83: 3800– 3807
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Plenum Press, New York
About this chapter
Cite this chapter
Sweetenham, J. (1996). Lymphoblastic Lymphoma In Adults. In: Abraham, N.G., Asano, S., Brittinger, G., Maestroni, G.J.M., Shadduck, R.K. (eds) Molecular Biology of Hematopoiesis 5. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0391-6_20
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0391-6_20
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8031-3
Online ISBN: 978-1-4613-0391-6
eBook Packages: Springer Book Archive